Array BioPharma: Array's colorectal cancer data shows why Pfizer splashed out $11B for the biotech

Key to Pfizer's paying $11 billion for Array BioPharma were the positive early readouts from its triplet therapy for colorectal cancer. Now, the biotech has shown exactly how attractive that data are. But not all analysts agree it's good enough.